Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.

Response rates to cytotoxics in gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) vary; recent trials demonstrated lack of objective response rates in up to 70% of patients. Identification of predictive therapeutic biomarkers would be beneficial in the treatment of GEP. Selected markers with known or suspected capability of predicting response to cytotoxics or prognosis (Ki-67, p53, multidrug resistance protein-1 (MDR1), Akt, thymidylate synthase (TS), phosphatase and tensin homolog (PTEN), CA9, cluster of differentiation 34 (CD34), vascular endothelial growth factor (VEGF), hypoxia-inducible factor (HIF)-1, mismatch repair gene - human mutL homolog 1 (hLMH1), and Bcl-2) were analyzed using immunohistochemisrtry in 60 treatment-naive patients receiving chemotherapy (n=46) or chemoembolization (n=14) for inoperable advanced and/or metastatic GEP and correlated with prognosis (survival and response rates). Therapy included systemic chemotherapy with streptozotocin (n=28), doxorubicin (n=14), 5-fluorouracil (n=18), and etoposide/cisplatinum (n=16), or chemoembolization (streptozotocin, 9; doxorubicin, 5). Factors associated with overall survival in the entire cohort were Ki-67, P<0.001; tumor grade, P<0.001; tumor differentiation, P<0.001; CA9, P=0.004; Akt, P=0.01; HIF-1, P<0.001; p53, P<0.0001; and hMLH1, P=0.005. Markers associated with treatment response included overall group: Akt and PTEN (P=0.05 and 0.05 respectively); streptozotocin: Akt (P=0.07), TS (P=0.02), and PTEN (P=0.017); doxorubicin: Ki-67 (P=0.05), Akt (P=0.06), and CA9 (P=0.02). At multivariate analysis, Akt was significantly associated with a nonresponse to therapy (objective response (OR): 0.2 (0.05-0.8)). For patients receiving only systemic chemotherapy (n=46), PTEN (0.04) and hLMH1 (0.03) were correlated with treatment response and for individual molecules were streptozotocin: PTEN (P=0.008) and hLMH1 (0.07); doxorubicin: Akt (P=0.09), CA9 (P=0.09), and hLMH1 (P=0.09). These results demonstrate a number of new prognostic biomarkers in GEP-NET, and in addition, response to chemotherapy was correlated with a simple panel of selected markers (such as CA9, Akt, PTEN, TS, and hLMH1).

[1]  N. Funel,et al.  PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Steyerberg,et al.  Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Lenz,et al.  Thymidylate synthase gene variations: predictive and prognostic markers , 2009, Molecular Cancer Therapeutics.

[4]  F. Boccardo,et al.  Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. , 2009, Anticancer research.

[5]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Hung,et al.  Induction of Akt activity by chemotherapy confers acquired resistance. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[7]  S. Fox,et al.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy , 2009, British Journal of Cancer.

[8]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[9]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[10]  P. Bedossa,et al.  Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors , 2008, Clinical Cancer Research.

[11]  S. Willich,et al.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.

[12]  K. Miyazaki,et al.  Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. , 2008, Oncology reports.

[13]  G. Scagliotti,et al.  Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors , 2008, Clinical Cancer Research.

[14]  F. Meric-Bernstam,et al.  Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. , 2007, Endocrine-related cancer.

[15]  A. Scarpa,et al.  Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary , 2007, Neuroendocrinology.

[16]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[17]  Carmen Blanco-Aparicio,et al.  PTEN, more than the AKT pathway. , 2007, Carcinogenesis.

[18]  P. Bedossa,et al.  Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. , 2006, Gastroenterology.

[19]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[20]  R. Callaghan,et al.  Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. , 2006, Current opinion in pharmacology.

[21]  D. O'Toole.  Tumeurs endocrines de l’estomac, de l’intestin grêle, du côlon et du rectum , 2006 .

[22]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[23]  P. Ruszniewski,et al.  Chemotherapy for Gastro-Enteropancreatic Endocrine Tumours , 2004, Neuroendocrinology.

[24]  M. Sekiguchi,et al.  Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer , 2003, Gastric Cancer.

[25]  P. Dhawan,et al.  Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. , 2002, Cancer Research.

[26]  C. Axiotis,et al.  Differential Expression of the PTEN Tumor Suppressor Protein in Fetal and Adult Neuroendocrine Tissues and Tumors: Progressive Loss of PTEN Expression in Poorly Differentiated Neuroendocrine Neoplasms , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[27]  M. Fukushima,et al.  Prognostic significance of thymidylate synthase activity in bladder carcinoma , 2001, Cancer.

[28]  D. Harpole,et al.  The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P Komminoth,et al.  Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. , 2000, The American journal of pathology.

[30]  M. Fukushima,et al.  Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. , 2000, International journal of oncology.

[31]  R. Gelber,et al.  Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Doglioni,et al.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. , 2009, Human pathology.

[33]  K. Syrjänen,et al.  Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. , 2008, Oncology reports.

[34]  M. Dewhirst,et al.  RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  D. O’Toole.  [Current trend: endocrine tumors of the stomach, small bowel, colon and rectum]. , 2006, Gastroenterologie clinique et biologique.